Symbols

LYEL

Lyell Immunopharma·NASDAQ

--(--)

Signals Analysis

Bullish signal 5

Bearish signal 1

Consensus Rating "Buy"

MACD Golden Cross

Ample Liquidity

High Gross Profit Margin

Significant Revenue Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About LYEL

Lyell Immunopharma, Inc.

A clinical‑stage T-cell reprogramming company that develops curative cell therapies for solid tumors

Industry

Biological Technology

Established Date

06/29/2018

Listing Date

06/17/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

161

Fiscal Year Ends

12-31

Website

www.lyell.com

Security Type

Common stock

Office address

201 Haskins Way, South San Francisco, California 94080

Business

Introduction

Lyell Immunopharma, Inc., was incorporated in Delaware on June 29, 2018. The Company is a late-stage clinical cell therapy company that is advancing a proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidate for cancer patients. The company's goal is to realize the full therapeutic potential of cell therapy for patients with hematological malignancies and solid tumors. To achieve this goal, the company is pioneering new approaches aimed at generating T-cell therapies to drive durable clinical responses. The company's CAR T cell product candidates start by identifying promising cancer targets. The company then designs the patient's own living immune cells and provides them with innovative enhancements, including CAR construction, technology and manufacturing protocols designed to give T cells a stronger cancer-killing ability.

Company Financials

EPS

LYEL has released its 2025 Q4 earnings. EPS was reported at -1.94, versus the expected -2.23, beating expectations. The chart below visualizes how LYEL has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

LYEL has released its 2025 Q4 earnings report, with revenue of 6.00K, reflecting a YoY change of -45.45%, and net profit of -140.72M, showing a YoY change of 26.68%. The Sankey diagram below clearly presents LYEL's revenue sources and cost distribution.